| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ... Cancer research 68 (19), 8022-8030, 2008 | 926 | 2008 |
| Protein phosphatase 2A regulatory subunits and cancer PJA Eichhorn, MP Creyghton, R Bernards Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1795 (1), 1-15, 2009 | 696 | 2009 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ... Oncogene 30 (22), 2547-2557, 2011 | 623 | 2011 |
| Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ... Cancer research 68 (22), 9221-9230, 2008 | 594 | 2008 |
| USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma PJA Eichhorn, L Rodón, A Gonzàlez-Juncà, A Dirac, M Gili, ... Nature medicine 18 (3), 429-435, 2012 | 449 | 2012 |
| Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ... Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011 | 390 | 2011 |
| Platforms for investigating LncRNA functions JL Charles Richard, PJA Eichhorn SLAS TECHNOLOGY: Translating Life Sciences Innovation 23 (6), 493-506, 2018 | 187 | 2018 |
| RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer V Serra, PJA Eichhorn, C García-García, YH Ibrahim, L Prudkin, ... The Journal of clinical investigation 123 (6), 2551-2563, 2013 | 152 | 2013 |
| PR72, a novel regulator of Wnt signaling required for Naked cuticle function MP Creyghton, G Roël, PJA Eichhorn, EM Hijmans, I Maurer, O Destrée, ... Genes & development 19 (3), 376-386, 2005 | 96 | 2005 |
| Deubiquitinases in cancer G Dewson, PJA Eichhorn, D Komander Nature Reviews Cancer 23 (12), 842-862, 2023 | 90 | 2023 |
| A giant novel gene undergoing extensive alternative splicing is severed by a Cornelia de Lange-associated translocation breakpoint at 3q26. 3 ET Tonkin, M Smith, P Eichhorn, S Jones, B Imamwerdi, S Lindsay, ... Human genetics 115, 139-148, 2004 | 72 | 2004 |
| c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression WJ Sim, PV Iyengar, D Lama, SKL Lui, HC Ng, L Haviv-Shapira, ... Nature communications 10 (1), 4349, 2019 | 67 | 2019 |
| USP 26 regulates TGF‐β signaling by deubiquitinating and stabilizing SMAD 7 S Kit Leng Lui, PV Iyengar, P Jaynes, ZFBA Isa, B Pang, TZ Tan, ... EMBO reports 18 (5), 797-808, 2017 | 63 | 2017 |
| Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity SCE Wright, N Vasilevski, V Serra, J Rodon, PJA Eichhorn Cancers 13 (7), 1538, 2021 | 62 | 2021 |
| PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle MP Creyghton, G Roël, PJA Eichhorn, LC Vredeveld, O Destrée, ... Proceedings of the National Academy of Sciences 103 (14), 5397-5402, 2006 | 62 | 2006 |
| A RNA interference screen identifies the protein phosphatase 2A subunit PR55γ as a stress-sensitive inhibitor of c-SRC PJA Eichhorn, MP Creyghton, K Wilhelmsen, H van Dam, R Bernards PLoS genetics 3 (12), e218, 2007 | 61 | 2007 |
| Structural and functional characterization of ubiquitin variant inhibitors of USP15 J Teyra, AU Singer, FW Schmitges, P Jaynes, SKL Lui, MJ Polyak, N Fodil, ... Structure 27 (4), 590-605. e5, 2019 | 58 | 2019 |
| Deciphering the roles of lncRNAs in breast development and disease JLC Richard, PJA Eichhorn Oncotarget 9 (28), 20179, 2018 | 57 | 2018 |
| USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination PV Iyengar, P Jaynes, L Rodon, D Lama, KP Law, YP Lim, C Verma, ... Scientific reports 5 (1), 14733, 2015 | 54 | 2015 |
| Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies A Saei, M Palafox, T Benoukraf, N Kumari, PW Jaynes, PV Iyengar, ... Journal of Experimental Medicine 215 (7), 1913-1928, 2018 | 51 | 2018 |